JP2023551467A - ５’－ｏ－フェニルアセチルウリジン及び治療上の使用 - Google Patents

５’－ｏ－フェニルアセチルウリジン及び治療上の使用 Download PDF

Info

Publication number
JP2023551467A
JP2023551467A JP2023532125A JP2023532125A JP2023551467A JP 2023551467 A JP2023551467 A JP 2023551467A JP 2023532125 A JP2023532125 A JP 2023532125A JP 2023532125 A JP2023532125 A JP 2023532125A JP 2023551467 A JP2023551467 A JP 2023551467A
Authority
JP
Japan
Prior art keywords
compound
uridine
condition
mammalian subject
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023532125A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023551467A5 (https=
Inventor
ガルシア ローランド アレジャンドロ ガルシア
ジョエル エー． セイドフ
デイヴィッド マイケル シンプソン
ボーステル レイド ウォーレン ボン
Original Assignee
ウェルスタット セラピューティクス コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウェルスタット セラピューティクス コーポレイション filed Critical ウェルスタット セラピューティクス コーポレイション
Publication of JP2023551467A publication Critical patent/JP2023551467A/ja
Publication of JP2023551467A5 publication Critical patent/JP2023551467A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Indole Compounds (AREA)
JP2023532125A 2020-12-01 2021-11-30 ５’－ｏ－フェニルアセチルウリジン及び治療上の使用 Pending JP2023551467A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063119764P 2020-12-01 2020-12-01
US63/119,764 2020-12-01
PCT/US2021/061053 WO2022119784A1 (en) 2020-12-01 2021-11-30 5'-o-phenylacetyluridine and therapeutic use

Publications (2)

Publication Number Publication Date
JP2023551467A true JP2023551467A (ja) 2023-12-08
JP2023551467A5 JP2023551467A5 (https=) 2024-12-06

Family

ID=81854225

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023532125A Pending JP2023551467A (ja) 2020-12-01 2021-11-30 ５’－ｏ－フェニルアセチルウリジン及び治療上の使用

Country Status (16)

Country Link
US (1) US20230416292A1 (https=)
EP (2) EP4255563B1 (https=)
JP (1) JP2023551467A (https=)
KR (1) KR20230112118A (https=)
CN (1) CN116782912A (https=)
AU (1) AU2021391411A1 (https=)
BR (1) BR112023010517A2 (https=)
CA (1) CA3199559A1 (https=)
DK (1) DK4255563T3 (https=)
FI (1) FI4255563T3 (https=)
IL (1) IL303100A (https=)
LT (1) LT4255563T (https=)
MX (1) MX2023006343A (https=)
PL (1) PL4255563T3 (https=)
PT (1) PT4255563T (https=)
WO (1) WO2022119784A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT4210709T (pt) 2020-09-14 2026-02-04 Pharma Cinq Llc 2¿,3¿‐diacetiluridina substituída com acetoacetilo na posição 5¿
TW202317144A (zh) * 2021-06-14 2023-05-01 美商維納拓爾斯製藥公司 口服生物可利用的核苷類似物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0232094A (ja) * 1988-06-09 1990-02-01 Wellcome Found Ltd:The 抗感染性ヌクレオシド

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2526414B2 (ja) 1994-05-20 1996-08-21 工業技術院長 制ガン剤エステル化合物及びその製造方法
JP4408450B2 (ja) * 1994-07-01 2010-02-03 ウェルスタット セラピューティクス コーポレイション 全身性炎症および炎症性肝炎の処置のためのピリミジンヌクレオチド前駆体
EP1808177B1 (en) * 1999-02-23 2018-08-08 The Regents of The University of California Methods of treatment of mitochondrial disorders
SI2153870T1 (sl) * 2004-11-26 2014-05-30 Ucl Business Plc Sestavki, ki obsegajo ornitin in fenilacetat ali fenilbutirat, za zdravljenje hepatitične encefalopatije
GB0426141D0 (en) * 2004-11-26 2004-12-29 Ucl Biomedica Plc Treatment
PT2922576T (pt) * 2012-11-21 2018-01-24 Horizon Therapeutics Llc Métodos de administração e avaliação de fármacos sequestradores de azoto para o tratamento de encefalopatia hepática
PL3182980T3 (pl) * 2014-08-19 2021-04-19 Wellstat Therapeutics Corporation Leczenie chorób niedoboru glikozylacji
AU2019215105B2 (en) * 2018-02-01 2024-12-19 Pharma Cinq, Llc Compositions and devices for systemic delivery of uridine
WO2022089612A1 (zh) * 2020-10-30 2022-05-05 上海岸阔医药科技有限公司 尿苷衍生物在制备药物中的应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0232094A (ja) * 1988-06-09 1990-02-01 Wellcome Found Ltd:The 抗感染性ヌクレオシド

Also Published As

Publication number Publication date
PL4255563T3 (pl) 2026-04-20
EP4255563B1 (en) 2025-12-31
WO2022119784A1 (en) 2022-06-09
AU2021391411A1 (en) 2023-07-20
IL303100A (en) 2023-07-01
EP4711007A2 (en) 2026-03-18
PT4255563T (pt) 2026-03-24
MX2023006343A (es) 2023-06-12
CN116782912A (zh) 2023-09-19
BR112023010517A2 (pt) 2024-02-06
KR20230112118A (ko) 2023-07-26
EP4255563A1 (en) 2023-10-11
FI4255563T3 (fi) 2026-03-13
EP4711007A3 (en) 2026-04-01
AU2021391411A9 (en) 2024-07-18
CA3199559A1 (en) 2022-06-09
EP4255563A4 (en) 2024-09-11
DK4255563T3 (da) 2026-03-16
LT4255563T (lt) 2026-04-10
US20230416292A1 (en) 2023-12-28

Similar Documents

Publication Publication Date Title
JP3474073B2 (ja) ウリジンまたはシチジンのアシル誘導体を含有する医薬組成物
JP2637534B2 (ja) アシルデオキシリボヌクレオシド誘導体およびその使用
EP2061749B1 (en) Positively charged water-soluble prodrugs of acetaminophen and related compounds with very fast skin penetration rate
US11547681B2 (en) N-acylethanolamide derivatives and uses thereof
US20020035086A1 (en) Acylated uridine and cytidine and uses thereof
EP0601322A2 (en) Adenosindeaminase inhibitor
CN101704874A (zh) 五环三萜及其衍生物的二甲双胍盐、其制备方法及医药用途
JP2023551467A (ja) ５’－ｏ－フェニルアセチルウリジン及び治療上の使用
CN111635309B (zh) 一种新型解热镇痛药物及其制备方法和用途
CN111635315B (zh) 一种解热镇痛药物及其制备方法和用途
JP2023541919A (ja) ５’位をアセトアセチルで置換した２’，３’－ジアセチルウリジン
JPH02502189A (ja) システインの新規な誘導体
US4080442A (en) Disaccharide derivatives used in the treatment of hepatic diseases
JPH07118156A (ja) アデノシンデアミナーゼ阻害剤
CN120000653B (zh) 贝曲沙班或其药学上可接受的盐在用于制备抗病毒药物中的用途
JPH01199961A (ja) タウリン誘導体、その製法及びこれを含有する薬剤組成物
JPS6140206B2 (https=)
CN120865317A (zh) 一种胞苷核苷类化合物的应用
RU2483066C1 (ru) Новое антитромботическое и антиатеросклеротическое средство и способ его получения (варианты)
EP2738167B1 (en) Novel antithrombotic and antiatherosclerotic agent and method for producing same (variants)
WO2019159868A1 (ja) 大腸炎改善剤
HK1005740B (en) Acylated uridine and cytidine and uses thereof

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20240510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260318

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260406